The European Commission approved Fotivda tivozanib from Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) to treat advanced renal cell carcinoma. Specifically, the approval is for first-line treatment of adults with
Read the full 278 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury